An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment

Novo Nordisk A/S509 enrolled

Overview

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 in subjects with type 2 diabetes under normal clinical practice conditions

Study Type

OBSERVATIONAL

Enrollment

509

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation

Eligibility

Sex: ALLMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Type 2 diabetes * Insulin-naive or previously treated by basal only insulin therapy Exclusion Criteria: * Patients who are unlikely to comply with the protocol * Pregnancy or breastfeeding or intention of becoming pregnant

Locations (1)

Novo Nordisk Investigational Site

Lahti, Finland

Outcomes

Primary Outcomes

The number of serious adverse drug reactions, including major hypoglycaemic events

Time frame: at 26 weeks

Secondary Outcomes

The number of all hypoglycaemic events

Time frame: at 26 weeks

HbA1c

Time frame: at 12 weeks and 26 weeks

Fasting plasma glucose at visits

Time frame: at 12 weeks and 26 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.